Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).

Omadacycline is a derivative of minocycline and the first agent of the aminomethylcycline class. A total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong) and Taiwan. Susceptibility testing was performed by broth microdilution methods in a central laboratory (JMI Laboratories). The collection included Gram-positive and Gram-negative organisms from patients with pneumonia, bloodstream, skin, community-acquired respiratory, and other infections. Omadacycline was very potent against ( = 689; MIC, 0.12/0.25 mg/liter), including methicillin-resistant (MRSA; = 299; MIC, 0.12/0.5 mg/liter), and had similar activity across geographic regions. Omadacycline was very active against (highest MIC, 0.25 mg/liter), β-hemolytic streptococci (highest MIC, 1 mg/liter), viridans group streptococci (highest MIC, 0.25 mg/liter), and spp. (highest MIC, 0.5 mg/liter) from all geographic regions. Overall, 53.8% of isolates were penicillin resistant (penicillin MIC, ≥2 mg/liter) and 10.7% of enterococci (21.2% among isolates) were vancomycin resistant. Omadacycline was active against (MIC, 0.5/1 mg/liter) regardless of β-lactamase production and was active against (MIC, ≤0.12/0.25 mg/liter). Against , omadacycline was most active against (MIC, 1/2 mg/liter), (MIC, 1/4 mg/liter), and (MIC, 2/4 mg/liter). Omadacycline had potent activity against Gram-positive and Gram-negative pathogens isolated from China and Taiwan and retained activity against problem pathogens, such as MRSA, vancomycin-resistant enterococci (VRE), penicillin-resistant (PRSPN), and extended-spectrum β-lactamase-producing The observed MIC profile in Chinese isolates was very similar to that seen in the U.S. and European surveillance studies.